Summary of clinical trial outcomes on some MET inhibitors, specifically targeting exon 14 EMs
| Study design | Cancer type and study population (MET positive) | MET alteration type & therapy | ORR (%) | mPFS and OS (months) |
|---|---|---|---|---|
Phase I (NCT00585195) PROFILE 1001 | NSCLC, n = 69 (65 evaluable) | MET exon 14 alteration Crizotinib 250 mg BID in continuous 28-day cycles | 32 (95% CI) | 7.3 (95% CI, 5.4–9.1) and 20.5 (95% CI, 14.3–21.8) |
Phase II (NCT02864992) VISION study | NSCLC (advanced/metastatic), n = 169 (152 received treatment) | MET exon 14 alteration SM Tepotinib 500 mg OD | Independent review 46%; investigator assessment 56% | 17.1 |
| Phase II (NCT02414139) | NSCLC (stage IIIB/IV), n = 97 (cohort 4:69 points; cohort 5:28 points) | MET exon 14 alteration SM Capmatinib 400 mg BID | Cohort 4: 41%; cohort 5b: 68% | NR |
| Phase II, (NCT02897479) | PSC; NSCLC, n = 593 [70 (60 evaluable: 25 PSC, 45 other NSCLC)] | MET exon 14 alteration SM Savolitinib (oral intake) 600 mg (for weight more or equal to 50 kg) and 400 mg (for weight less than 50 kg) until disease progression or intolerable toxicity OD | Tumor response evaluable set: 49.2 (95% CI, 36.1–62.3); FAS 42.9 (95% CI, 31.1–55.3) | 12.5 (95% CI, 10.5–23.6) |
BID: twice a day; OD: once a day; CI: confidence interval; n: number of people
The authors would like to thank the School of Chemical Sciences and School of Life Sciences, Central University of Gujarat, ICAR National Research Centre for Equines, Government of India and Amity Institute of Biotechnology for infrastructural and round-the-clock internet facilities.
PM and RR: Conceptualization, Writing—original draft. PM, RR, RS, VHP and TKM: Writing—review & editing. PM and TKM: Validation, Supervision. All authors read and approved the submitted version.
The author declares that there are no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.